OBJECTIVE: In 1995, an analysis showed an inferior prognosis after rectal cancer in Denmark compared with the other Scandinavian countries. The Danish Colorectal Cancer Group (DCCG) was established with the aim of improving the prognosis, and in this study we present a survival analysis of patients treated from 1994 to 2006. METHOD: The study was based on the National Rectal Cancer Registry and the National Colorectal Cancer Database, supplemented with data from the Central Population Registry. The analysis included actuarial overall and relative survival. RESULTS: A total of 10 632 patients were operated on. The overall 5-year survival increased from 0.37 in 1994 to 0.51% in 2006; the improvement was greater in men (20% points) than in women (10% points), and greatest in stage III (20% points). The relative 5-year survival increased from 0.46 to 0.62, including an improvement of 23% points in men and 9% points in women and the greatest in stage III (22% points). CONCLUSIONS: The prognosis has improved substantially, probably mainly because of initiatives taken by the DCCG, among which implementation of total mesorectal excision, improved staging and centralized treatment are considered most important.
OBJECTIVE: In 1995, an analysis showed an inferior prognosis after rectal cancer in Denmark compared with the other Scandinavian countries. The Danish Colorectal Cancer Group (DCCG) was established with the aim of improving the prognosis, and in this study we present a survival analysis of patients treated from 1994 to 2006. METHOD: The study was based on the National Rectal Cancer Registry and the National Colorectal Cancer Database, supplemented with data from the Central Population Registry. The analysis included actuarial overall and relative survival. RESULTS: A total of 10 632 patients were operated on. The overall 5-year survival increased from 0.37 in 1994 to 0.51% in 2006; the improvement was greater in men (20% points) than in women (10% points), and greatest in stage III (20% points). The relative 5-year survival increased from 0.46 to 0.62, including an improvement of 23% points in men and 9% points in women and the greatest in stage III (22% points). CONCLUSIONS: The prognosis has improved substantially, probably mainly because of initiatives taken by the DCCG, among which implementation of total mesorectal excision, improved staging and centralized treatment are considered most important.
Authors: Kyle Freischlag; Zhifei Sun; Mohamed A Adam; Jina Kim; Manisha Palta; Brian G Czito; John Migaly; Christopher R Mantyh Journal: JAMA Surg Date: 2017-06-01 Impact factor: 14.766
Authors: Kerollos N Wanis; Karen Pineda-Solis; Mauro E Tun-Abraham; Jake Yeoman; Stephen Welch; Kelly Vogt; Julie Ann M Van Koughnett; Michael Ott; Roberto Hernandez-Alejandro Journal: Hepatobiliary Surg Nutr Date: 2017-06 Impact factor: 7.293
Authors: G Gagliardi; S Pucciarelli; C R Asteria; A Infantino; G Romano; B Cola; P De Nardi; M Brulatti; M Lambertini; E Contessini-Avesani; G Casula; C Coco; D D'Amico; F F Selvaggi; C Eccher; G D'Ambrosio; F Galeotti; E Jovine; I Demma; A Fianchini; G Ambrosino; L M Casentino; M Fiorino Journal: Tech Coloproctol Date: 2010-07-15 Impact factor: 3.781
Authors: Gretchen C Edwards; Adriana C Gamboa; Michael P Feng; Roberta L Muldoon; Michael B Hopkins; Sherif Abdel-Misih; Glen C Balch; Jennifer Holder-Murray; Maryam Mohammed; Scott E Regenbogen; Matthew L Silviera; Alexander T Hawkins Journal: Surgery Date: 2021-09-24 Impact factor: 4.348
Authors: David Hersi Smith; Ib Jarle Christensen; Niels Frank Jensen; Bo Markussen; Sven Müller; Hans Jørgen Nielsen; Nils Brünner; Kirsten Vang Nielsen Journal: BMC Cancer Date: 2013-10-21 Impact factor: 4.430